Bright Uro Inc. secured U.S. FDA 510(k) clearance for the Glean abdominal sensor, which expands the capabilities of its Glean urodynamics system to enable multichannel urodynamic studies. The new sensor will allow clinicians to perform multichannel urodynamics, capturing both abdominal and detrusor pressures without the need for catheters, supporting treatment decision-making for patients with lower urinary tract dysfunction and other urological conditions.

Boston Scientific Corp.’s Rezūm Water Vapor Therapy is superior at providing symptom relief for men with benign prostatic hyperplasia (BPH) than combination drug therapy, according to 12-month data from the Vapeur clinical trial. Patients treated with Rezūm, a minimally invasive therapy, also saw a better preservation of their sexual function.

Boston Scientific Corp. plans to acquire Valencia Technologies Corp. in the first half of 2026 in a move that will expand its urology portfolio. Valencia makes the Ecoin system, an implantable tibial nerve stimulator (ITNS) designed to treat urge urinary incontinence (UUI). The companies did not disclose terms of the deal, which is not expected to have a material impact on 2026 earnings per share.